Early-Stage Bioerodible Sustained-Release Technologies Designed for the Treatment of Retinal Diseases SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic
Awards Open to San Diego, Los Angeles and San Francisco Bay Area Nominees SAN DIEGO–(BUSINESS WIRE)–#BayArea–Biocom, the association representing the
Biosimilars Market By Product, By Technology, Indication, Manufacturing Type, Route of Administration, Geography – Global Markets 2014-2018 & 2019-2024 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Biosimilars Market By Product, By Technology, By Indication, By Manufacturing Type, By Route of Administration, by Geography –
JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Tracleer®1 (bosentan)
LUGANO, Switzerland–(BUSINESS WIRE)–#Antiaging–Contrad Swiss, a pharmaceutical company focused on breakthrough, innovative products that reframe the world of medicine, announces a
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Primary Sclerosing Cholangitis” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the
Global Coalition for Adaptive Research’s Innovative Clinical Trial Platform Opens to Evaluate New Therapies for Brain Cancer
LEXINGTON, Mass.–(BUSINESS WIRE)–#GBMAGILE–The Global Coalition for Adaptive Research (GCAR) announced today that the GBM AGILE (Glioblastoma Adaptive Global Innovative Learning
AstraZeneca’s Bevespi Aerosphere has been approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease, becoming the first approved fixed-dose, long-acting dual bronchodilator in a pressurised metered-dose inhaler device in Japan.
AstraZeneca and Merck revealed Wednesday that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, the only PARP inhibitor approved in Japan .
The list features the top 50 biopharma companies by 2018 prescription sales CRANBURY, N.J.–(BUSINESS WIRE)–#pharma—Pharmaceutical Executive, a multimedia platform for
Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline
Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.
ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.
@alvogenpr subsidiary in Taiwan, Lotus Pharmaceuticals today announced capital and business collaboration agreements with Fuji Pharma in Japan, as Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.
BOSTON–(BUSINESS WIRE)–Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI)
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is an innovative biotechnology company focusing on research and production of cannabinoids. The company utilizes its
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather
First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute
STERLING, Kan.–(BUSINESS WIRE)–Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient
2018 Full-year results and business update Clinical trials set to announce key data in 2019 Invir.IO™ platform designed to deliver
SHANGHAI–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Shanghai?src=hash" target="_blank"gt;#Shanghailt;/agt;–To accelerate the development of cell and gene therapy, ATLATL Center and Miltenyi Biotec have cooperated to build ATLATL-MACS Center
ANN ARBOR, Mich. & LANSING, Mich.–(BUSINESS WIRE)–Michigan’s premier biosciences industry trade organization, MichBio, presents its annual Michigan Biosciences Day at